Accurate chromosome segregation is vital for cell viability. Many cancer cells show chromosome instability (CIN) due to aberrant expression of the genes involved in chromosome segregation. The induction of massive chromosome segregation errors in such cancer cells by small molecule inhibitors is an emerging strategy to kill these cells selectively. Here we screened and characterized small molecule inhibitors which cause mitotic chromosome segregation errors to target cancer cell growth. We screened about 300 chemicals with known targets, and found that Rho-associated coiled-coil kinase (ROCK) inhibitors bypassed the spindle assembly checkpoint (SAC), which delays anaphase onset until proper kinetochore-microtubule interactions are established. We investigated how ROCK inhibitors affect chromosome segregation, and found that they induced microtubule-dependent centrosome fragmentation. Knockdown of ROCK1 and ROCK2 revealed their additive roles in centrosome integrity. Pharmacological inhibition of LIMK also induced centrosome fragmentation similar to that by ROCK inhibitors. Inhibition of ROCK or LIMK hyper-stabilized mitotic spindles and impaired Aurora-A activation. These results suggested that ROCK and LIMK are directly or indirectly involved in microtubule dynamics and activation of Aurora-A. Furthermore, inhibition of ROCK or LIMK suppressed T cell leukemia growth in vitro, but not peripheral blood mononuclear cells. They induced centrosome fragmentation and apoptosis in T cell leukemia cells. These results suggested that ROCK and LIMK can be a potential target for anti-cancer drugs.
References
[1]
Holland AJ, Cleveland DW (2012) Losing balance: the origin and impact of aneuploidy in cancer. EMBO Rep 13: 501–514. doi: 10.1038/embor.2012.55
[2]
Chi YH, Jeang KT (2007) Aneuploidy and cancer. J Cell Biochem 102: 531–538. doi: 10.1002/jcb.21484
[3]
Thompson SL, Bakhoum SF, Compton DA (2010) Mechanisms of chromosomal instability. Curr Biol 20: R285–295. doi: 10.1016/j.cub.2010.01.034
[4]
Musacchio A, Salmon ED (2007) The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 8: 379–393. doi: 10.1038/nrm2163
[5]
Kops GJ, Foltz DR, Cleveland DW (2004) Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A 101: 8699–8704. doi: 10.1073/pnas.0401142101
[6]
Janssen A, Kops GJ, Medema RH (2009) Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc Natl Acad Sci U S A 106: 19108–19113. doi: 10.1073/pnas.0904343106
[7]
Hardwicke MA, Oleykowski CA, Plant R, Wang J, Liao Q, et al. (2009) GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther 8: 1808–1817. doi: 10.1158/1535-7163.mct-09-0041
[8]
Farrell P, Shi L, Matuszkiewicz J, Balakrishna D, Hoshino T, et al. (2013) Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor. Mol Cancer Ther 12: 460–470. doi: 10.1158/1535-7163.mct-12-0657
[9]
Colombo R, Caldarelli M, Mennecozzi M, Giorgini ML, Sola F, et al. (2010) Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res 70: 10255–10264. doi: 10.1158/0008-5472.can-10-2101
[10]
Tardif KD, Rogers A, Cassiano J, Roth BL, Cimbora DM, et al. (2011) Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1. Mol Cancer Ther 10: 2267–2275. doi: 10.1158/1535-7163.mct-11-0453
[11]
Shan W, Akinfenwa PY, Savannah KB, Kolomeyevskaya N, Laucirica R, et al. (2012) A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma. Clin Cancer Res 18: 3352–3365. doi: 10.1158/1078-0432.ccr-11-3058
[12]
Tannous BA, Kerami M, Van der Stoop PM, Kwiatkowski N, Wang J, et al.. (2013) Effects of the Selective MPS1 Inhibitor MPS1-IN-3 on Glioblastoma Sensitivity to Antimitotic Drugs. J Natl Cancer Inst.
[13]
Cimini D (2008) Merotelic kinetochore orientation, aneuploidy, and cancer. Biochim Biophys Acta 1786: 32–40. doi: 10.1016/j.bbcan.2008.05.003
[14]
Yang Z, Kenny AE, Brito DA, Rieder CL (2009) Cells satisfy the mitotic checkpoint in Taxol, and do so faster in concentrations that stabilize syntelic attachments. J Cell Biol 186: 675–684. doi: 10.1083/jcb.200906150
[15]
Fan L, Pellegrin S, Scott A, Mellor H (2010) The small GTPase Rif is an alternative trigger for the formation of actin stress fibers in epithelial cells. J Cell Sci 123: 1247–1252. doi: 10.1242/jcs.061754
[16]
Katayama H, Wang J, Treekitkarnmongkol W, Kawai H, Sasai K, et al. (2012) Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73. Cancer Cell 21: 196–211. doi: 10.1016/j.ccr.2011.12.025
[17]
Fukazawa H, Noguchi K, Murakami Y, Uehara Y (2002) Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway. Mol Cancer Ther 1: 303–309.
[18]
Sakaue-Sawano A, Kobayashi T, Ohtawa K, Miyawaki A (2011) Drug-induced cell cycle modulation leading to cell-cycle arrest, nuclear mis-segregation, or endoreplication. BMC Cell Biol 12: 2. doi: 10.1186/1471-2121-12-2
[19]
Santaguida S, Tighe A, D'Alise AM, Taylor SS, Musacchio A (2010) Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine. J Cell Biol 190: 73–87. doi: 10.1083/jcb.201001036
[20]
Santaguida S, Vernieri C, Villa F, Ciliberto A, Musacchio A (2011) Evidence that Aurora B is implicated in spindle checkpoint signalling independently of error correction. EMBO J 30: 1508–1519. doi: 10.1038/emboj.2011.70
[21]
Wysong DR, Chakravarty A, Hoar K, Ecsedy JA (2009) The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents. Cell Cycle 8: 876–888. doi: 10.4161/cc.8.6.7897
[22]
De Luca M, Brunetto L, Asteriti IA, Giubettini M, Lavia P, et al. (2008) Aurora-A and ch-TOG act in a common pathway in control of spindle pole integrity. Oncogene 27: 6539–6549. doi: 10.1038/onc.2008.252
[23]
Oshimori N, Ohsugi M, Yamamoto T (2006) The Plk1 target Kizuna stabilizes mitotic centrosomes to ensure spindle bipolarity. Nat Cell Biol 8: 1095–1101. doi: 10.1038/ncb1474
[24]
Torres JZ, Summers MK, Peterson D, Brauer MJ, Lee J, et al. (2011) The STARD9/Kif16a kinesin associates with mitotic microtubules and regulates spindle pole assembly. Cell 147: 1309–1323. doi: 10.1016/j.cell.2011.11.020
[25]
Amano M, Nakayama M, Kaibuchi K (2010) Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken) 67: 545–554. doi: 10.1002/cm.20472
[26]
Sumi T, Hashigasako A, Matsumoto K, Nakamura T (2006) Different activity regulation and subcellular localization of LIMK1 and LIMK2 during cell cycle transition. Exp Cell Res 312: 1021–1030. doi: 10.1016/j.yexcr.2005.12.030
[27]
Heng YW, Lim HH, Mina T, Utomo P, Zhong S, et al. (2012) TPPP acts downstream of RhoA-ROCK-LIMK2 to regulate astral microtubule organization and spindle orientation. J Cell Sci 125: 1579–1590. doi: 10.1242/jcs.096818
[28]
Ross-Macdonald P, de Silva H, Guo Q, Xiao H, Hung CY, et al. (2008) Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol Cancer Ther 7: 3490–3498. doi: 10.1158/1535-7163.mct-08-0826
[29]
Asteriti IA, Giubettini M, Lavia P, Guarguaglini G (2011) Aurora-A inactivation causes mitotic spindle pole fragmentation by unbalancing microtubule-generated forces. Mol Cancer 10: 131？.
[30]
Shimokawa H, Hiramori K, Iinuma H, Hosoda S, Kishida H, et al. (2002) Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol 40: 751–761. doi: 10.1097/00005344-200211000-00013
[31]
Wen Q, Goldenson B, Silver SJ, Schenone M, Dancik V, et al. (2012) Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell 150: 575–589. doi: 10.1016/j.cell.2012.06.032
[32]
Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, et al. (2010) Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 55: 26–34. doi: 10.1002/pbc.22430
[33]
Tomita M, Mori N (2010) Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro. Cancer Sci 101: 1204–1211. doi: 10.1111/j.1349-7006.2010.01499.x
[34]
Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, et al. (2011) The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med 15: 2057–2070. doi: 10.1111/j.1582-4934.2010.01218.x
[35]
Ritchey L, Ottman R, Roumanos M, Chakrabarti R (2012) A functional cooperativity between Aurora A kinase and LIM kinase1: implication in the mitotic process. Cell Cycle 11: 296–309. doi: 10.4161/cc.11.2.18734
[36]
Johnson EO, Chang KH, Ghosh S, Venkatesh C, Giger K, et al. (2012) LIMK2 is a crucial regulator and effector of Aurora-A-kinase-mediated malignancy. J Cell Sci 125: 1204–1216. doi: 10.1242/jcs.092304
[37]
Petrilli A, Copik A, Posadas M, Chang LS, Welling DB, et al.. (2013) LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2. Oncogene.
[38]
Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8: 547–566. doi: 10.1038/nrd2907
[39]
Bergnes G, Brejc K, Belmont L (2005) Mitotic kinesins: prospects for antimitotic drug discovery. Curr Top Med Chem 5: 127–145. doi: 10.2174/1568026053507697
[40]
Jones R, Vuky J, Elliott T, Mead G, Arranz JA, et al. (2013) Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Invest New Drugs 31: 1001–1007. doi: 10.1007/s10637-013-9926-y
[41]
Ikezoe T, Yang J, Nishioka C, Tasaka T, Taniguchi A, et al. (2007) A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther 6: 1851–1857. doi: 10.1158/1535-7163.mct-07-0067
